Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

AbbVie is currently addressing serious health ... 30% from Western Europe, Canada, Japan and Australia and 40% from the fastest-growing economies, including India, China, Russia and Brazil.

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

There are several Canadian companies that offer funds that invest in U.S. stocks with a covered call strategy. One is ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond to prior biologic therapy.

We recently compiled a list of the Louis Navellier’s Top 15 Long-Term Stock Picks. In this article, we are going to take a ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

North Chicago, Illinois-based AbbVie Inc. (ABBV) focuses on creating medicines and solutions that address complex health issues and enhance people's lives through its core therapeutic areas ...